

# **Crohn's Disease (Regional Enteritis) (Gastrointestinal) - Drugs In Development, 2021**

<https://marketpublishers.com/r/C668794C51E3EN.html>

Date: July 2021

Pages: 839

Price: US\$ 2,500.00 (Single User License)

ID: C668794C51E3EN

## **Abstracts**

Crohn's Disease (Regional Enteritis) (Gastrointestinal) - Drugs In Development, 2021

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Drugs In Development, 2021, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 17, 41, 32, 3, 68, 31 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Crohn's Disease

(Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Crohn's Disease (Regional Enteritis) - Overview

Crohn's Disease (Regional Enteritis) - Therapeutics Development

Crohn's Disease (Regional Enteritis) - Therapeutics Assessment

Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics  
Development

Crohn's Disease (Regional Enteritis) - Drug Profiles

Crohn's Disease (Regional Enteritis) - Dormant Projects

Crohn's Disease (Regional Enteritis) - Discontinued Products

Crohn's Disease (Regional Enteritis) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Crohn's Disease (Regional Enteritis), 2021  
Number of Products under Development by Companies, 2021  
Number of Products under Development by Universities/Institutes, 2021  
Products under Development by Companies, 2021  
Products under Development by Universities/Institutes, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by 9 Meters Biopharma Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Abivax SA, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Aclaris Therapeutics Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Active Biotech AB, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Affilogic SAS, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by AIBIOS Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Alfasigma SpA, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Algernon Pharmaceuticals Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Alpha Cancer Technologies Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Alvotech ehf, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Amide Technologies Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Anterogen Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Artelo Biosciences Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Artizan Biosciences Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Asdera LLC, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Assembly Biosciences Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by AstraZeneca Plc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Atlantic Healthcare Plc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Avexegen Therapeutics Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Avobis Bio LLC, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Avotres Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Axim Biotechnologies Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Bio-Thera Solutions Ltd, 2021

Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by BioXpress Therapeutics SA, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim International GmbH, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Bristol-Myers Squibb Co, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Cellivory Therapeutics Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Celltrion Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Cellvation Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Celularity Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Cerecor Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by ChunLab Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Cloud Pharmaceuticals Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Curacle Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by CVasThera, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Cytocom Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Cytodyn Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Dadang & BIO Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies SA, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Defensin Therapeutics ApS, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Temisis Therapeutics, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Tetherex Pharmaceuticals Corp, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by The Cell Factory BVBA, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Theravance Biopharma Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Thetis Pharmaceuticals LLC, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by TRACT Therapeutics Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Trio Medicines Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by UCB SA, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Ventyx Biosciences Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by VHsquared Ltd, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by VITAbolus Inc, 2021

Crohn's Disease (Regional Enteritis) - Pipeline by Winston Pharmaceuticals Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by XBiotech Inc, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, 2021  
Crohn's Disease (Regional Enteritis) - Pipeline by Yom Chai, 2021  
Crohn's Disease (Regional Enteritis) - Dormant Projects, 2021  
Crohn's Disease (Regional Enteritis) - Discontinued Products, 2021



## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Crohn's Disease (Regional Enteritis), 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Top 10 Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021

## I would like to order

Product name: Crohn's Disease (Regional Enteritis) (Gastrointestinal) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/C668794C51E3EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C668794C51E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970